share_log

Raymond James Reinstates Outperform on Immunovant, Announces $36 Price Target

Benzinga ·  Oct 10 21:04  · Ratings

Raymond James analyst Danielle Brill reinstates Immunovant (NASDAQ:IMVT) with a Outperform and announces $36 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment